Tuesday 08 September 2020

Sirtex Medical announces strategic investment in Nanospectra Biosciences
WOBURN, Mass. (September 8, 2020) –– Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced a lead and strategic investment in Nanospectra Biosciences, Inc. (Nanospectra), a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, as part of Nanospectra’s Series B-1 round of financing.
Read more

Thursday 27 August 2020

Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone
WOBURN, Mass. (August 27, 2020) –– Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex and its shareholders, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), have been issued a "Notice of Drug Clinical Trial Approval" by the National Medical Products Administration (NMPA) of the People’s Republic of China.
Read more

Monday 24 August 2020

U.S. RESiN registry Sirtex Medical completes enrollment of landmark U.S. RESiN registry
WOBURN, Mass. (August 24, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, reports that enrollment in the U.S. RESiN Registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for a satisfactory number of patients enrolled for meaningful data analysis. Under the leadership and direction of Dr. Brown and the trial’s executive committee, the registry will close enrollment at the 45 centers centers and will move to a new phase of data review and evaluation, publication and presentation. The U.S. RESiN Registry, a database of patients eligible for treatment with SIR-Spheres® Y-90 resin microspheres, started enrollment in 2015 and represents one of the largest prospective, multicenter, observational studies conducted in interventional radiology and the field of interventional oncology.
Read more

Monday 17 August 2020

Sirtex Medical announces partnership with Magle Chemoswed
WOBURN, Mass. (August 17, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced a collaboration with Magle Chemoswed, a Malmö, Sweden-based contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis.
Read more

Wednesday 03 June 2020

Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development
WOBURN, Mass. (June 3, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Dr. Mark A. Turco, FACC, as Global Chief Medical Officer and EVP of Research & Development, effective June 1, 2020.
Read more

Wednesday 12 February 2020

Sirtex Medical announces collaboration with MIM Software Inc.
WOBURN, Mass. (February 12, 2020) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. Under the terms of the agreement, Sirtex’s specialized sales teams in the United States, Europe and other key global markets will offer MIM SurePlanTM LiverY90 software alongside the company’s SIR-Spheres® Y-90 resin microspheres to improve treatment precision for patients with hepatic tumors.
Read more


Download PDF Download PDF

Languages:

Monday 10 February 2020

Sirtex Medical Announces Closing of Strategic Transaction with OncoSec Medical, Inc.
WOBURN, Mass. (February 10, 2020) – Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, today announced that the shareholders of OncoSec Medical, Inc. (“OncoSec”) have approved, and the parties have closed, the strategic investment by and partnership with Sirtex and Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”). The signing of the strategic transaction was previously announced on October 10, 2019.
Read more

Wednesday 16 October 2019

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer
WOBURN, Mass. (October 16, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.
Read more

Thursday 10 October 2019

Sirtex Medical and China Grand Pharmaceutical announce a strategic transaction with OncoSec Medical Incorporated
PENNINGTON, N.J., Oct. 10, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (Nasdaq:ONCS), a late-stage intratumoral cancer immunotherapy company, today announced it entered into a strategic transaction with Grand Decade Developments Limited (Grand Decade), a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (HKG:512), and its affiliate, Sirtex Medical US Holdings, Inc. (Sirtex).
Read more

Monday 24 June 2019

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.* More than 1,000 healthcare providers and hospital systems across the globe offer this treatment.
Read more


Download PDF Download PDF

Languages:

Tuesday 11 October 2016

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Sirtex Medical Limited (ASX:SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.
Read more


Download PDF Download PDF

Languages:

Thursday 29 January 2015

FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Read more


Download PDF Download PDF

Languages:

Monday 08 September 2014

Sirtex Medical Inc. Expands Business into Brazil, Experiences Record Growth
First SIR-Spheres® microspheres treatment at Hospital Sirio-Libanes in Sao Paulo, Brazil
Read more

Saturday 13 April 2013

Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres® Microspheres as First-Line Treatment for Colorectal Liver Metastases
World’s Largest Interventional Oncology Study with More Than 500 Patients Enrolled
Read more

Tuesday 11 December 2012

Sirtex Medical Limited Launches New Global Website for SIR-Spheres® microspheres – a form of Selective Internal Radiation Therapy (SIRT) for Liver Tumours
www.sirtex.com informs doctors, patients and investors about the world’s most widely used and widely studied form of SIRT for all cancers in the liver
Read more

Wednesday 15 August 2012

Sirtex Medical Inc. Expands U.S. Operations to Accommodate Increased Demand for SIR-Spheres® Microspheres
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today expansion of U.S. operations with the placement of additional sales, marketing, and functional support staff in Massachusetts and across the country.
Read more

Thursday 07 July 2011

Six Year Study Confirms Sirtex´s Liver Cancer Therapy Safe and Effective

Thursday 24 June 2010

Sirtex Invests in New Major Asia Pacific Study to Expand Clinical Use

Tuesday 08 June 2010

SIRTEX Reports Positive Results From Asian Clinical Trial
Combination of SIR-Spheres® Microspheres and Chemotherapy Shows Improved Survival for Inoperable Hepatocellular Carcinoma (HCC) Liver Cancer Patients. Median overall survival of 11.75 months in a HCC patient population with limited treatment options
Read more

Monday 01 March 2010

New UK Trial With Oxford University To Test New Bowel Cancer Therapy
Oncology treatment company Sirtex Medical Limited (ASX: SRX) today announced the start of a new trial to see if chemotherapy used with SIR-Spheres® microspheres targeted radiation therapy is more effective than just chemotherapy in patients with bowel cancer that has spread to the liver.
Read more

Thursday 11 February 2010

Sirtex Joins Bayer Healthcare in Major European Liver Cancer Trial

Tuesday 01 July 2008

Fourth Annual Symposium on Liver-Directed Microsphere Therapy Raises Awareness of the Latest Advances for Treating Metastatic Liver Tumors
Clinical Symposium Featured New Data and Research on the use of Sirtex’s SIR-Spheres® Microspheres
Read more

Friday 13 June 2008

SIR-Spheres® Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting
Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center in New Orleans, La., is considered the premier educational and scientific event in the nuclear medicine community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has metastasized to the liver.
Read more

Thursday 24 April 2008

Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients with Inoperable Metastatic Liver Cancer
Meeting to Highlight Latest Clinical Advances with the Use of Yttrium-90 Microsphere Therapy to Control one of the Deadliest Forms of Cancer
Read more

Monday 31 March 2008

Sirtex Medical receives US FDA Approval to Proceed with FAST Clinical Trial
Update on Clinical Trial Evaluating SIR-Spheres Microspheres with Bevacizumab and Chemotherapy as a First-Line Treatment for Unresectable Metastatic Colorectal Cancer
Read more

Wednesday 03 October 2007

Sirtex Medical Signs Agreements with Peter MacCallum Cancer Centre to Develop and Market Innovative Cancer Treatment Technology

Wednesday 18 April 2007

Sirtex Medical Announces Expansion of its R&D Programs to Develop new Oncology Therapies and Product Enhancements

Tuesday 27 March 2007

Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Conference
New Data Regarding Repeat Treatments of SIR-Spheres® Microspheres in Patients with Advanced Liver Tumors to be Included at Annual Meeting
Read more

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage